SEARCH
= Registered usersPractitioner 2008;252(1705):19
Metformin reduces weight gain in patients on atypical antipsychotics
23 Apr 2008
Combination therapy with an atypical antipsychotic and metformin may be an attractively simple solution but more data from larger, long-term, preferably primary care-based trials are required to test this approach. In the meantime, we should be closely monitoring weight gain and cardiovascular risk in patients newly started on atypical antipsychotics, bearing in mind that the Framingham risk score underestimates risk in obese patients with the metabolic syndrome.
This article can be accessed only if you are a paid-up subscriber to The Practitioner.
To subscribe contact: thepractitioner@servicehelpline.co.uk
Overseas subscription
Individual: £138Institutional: £138
Overseas: +44 (0)1795 418 670
Subscription enquiry: thepractitioner@servicehelpline.co.uk
UK subscription
Individual: £85Institutional: £85
UK: 0844 815 5934
Subscription enquiry: thepractitioner@servicehelpline.co.uk